AeroRx Therapeutics
AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized LABA/LAMA (AERO-007) and LABA/LAMA/ICS (AERO-111) combination therapies for moderate-to-severe COPD patients underserved by handheld inhalers.
- Company typePrivate
- Founded2022
- HeadquartersLa Jolla, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What AeroRx Therapeutics does
AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic obstructive pulmonary disease (COPD). Founded in 2022 and headquartered at the Avalon BioVentures Accelerator in La Jolla, California, the company focuses on moderate-to-severe COPD patients who are underserved by handheld inhaler-based therapies due to dexterity limitations, advanced disease, or suboptimal response to inhaled bronchodilators.
The company's lead asset, AERO-007, is a nebulized fixed-dose combination of indacaterol (a long-acting beta2 agonist, LABA) and glycopyrrolate (a long-acting muscarinic antagonist, LAMA), positioned as the first nebulized LABA+LAMA in clinical development. The product is delivered via a 510(k)-cleared standard jet nebulizer (LC Sprint) and is being pursued as a once-daily first-line maintenance therapy. In July 2025, AeroRx reported positive topline Phase 2a data demonstrating placebo-adjusted FEV1 AUC0-24h of 251 mL and 262 mL at the two dose levels (p<0.001), with data presented at the ATS 2026 International Conference. A second candidate, AERO-111, is a nebulized LABA/LAMA/ICS triple combination in IND-enabling stage for patients who escalate beyond dual bronchodilation. Both programs leverage the FDA 505(b)(2) regulatory pathway using approved active pharmaceutical ingredients.
AeroRx is pre-revenue and funds operations through equity capital. In October 2025, the company closed a $21 million Series A led by Avalon BioVentures, with participation from Correlation Ventures and Alexandria Venture Investments, to fund Phase 2b dose-optimization and NDA preparation. Future revenue is expected from prescription pharmaceutical product sales through specialty pharmacies, healthcare systems, and durable medical equipment suppliers, contingent on NDA approval. The leadership team is led by co-founder and CEO Ahmet Tutuncu, MD, PhD, whose prior respiratory development work resulted in three successful NDAs/MAAs (Flutiform, Pulmicort HFA, Lonhala Magnair).
AeroRx Therapeutics firmographics
Firmographics- Name
- AeroRx Therapeutics
- Legal name
- AeroRx Therapeutics, Inc.
- Website
- https://aerorxtx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized LABA/LAMA (AERO-007) and LABA/LAMA/ICS (AERO-111) combination therapies for moderate-to-severe COPD patients underserved by handheld inhalers.
- Ownership category
- akta.pro rank
AeroRx Therapeutics industry classification
Industry- Product category
- COPD Therapeutics
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where AeroRx Therapeutics is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AeroRx Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through sales of prescription nebulized COPD therapies following successful clinical development, regulatory approval (NDA), and commercialization.
Go-to-market motion1 record
Marketing channels3 records
AeroRx Therapeutics product offering
Product offeringCore offering
AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized fixed-dose combination therapies for moderate-to-severe COPD. Its lead candidate AERO-007 combines indacaterol (LABA) and glycopyrrolate (LAMA) in a proprietary solution formulation for delivery via a standard 510(k)-cleared jet nebulizer, while AERO-111 extends the approach to a nebulized LABA+LAMA+ICS triple combination.
Product overview
AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases. The company operates a portfolio approach with two lead product candidates: AERO-007 (Phase 2), a nebulized LABA/LAMA fixed-dose combination of indacaterol and glycopyrrolate, represents the first nebulized dual bronchodilator in development as first-line COPD maintenance therapy; and AERO-111 (IND-enabling), a nebulized LABA/LAMA/ICS triple combination targeting patients who escalate beyond dual bronchodilators. Both products are delivered via standard 510(k)-cleared jet nebulizers, addressing the treatment gap for COPD patients who are underserved by handheld inhalers.
Differentiator
Problem solved
Functional benefit
Products and services
- AERO-007 Proprietary nebulized LABA/LAMA fixed-dose combination bronchodilator (indacaterol and glycopyrrolate) for moderate-to-severe COPD, delivered via a standard jet nebulizer. First nebulized LABA+LAMA combination in clinical development, positioned as once-daily first-line maintenance therapy for moderate-to-severe COPD patients underserved by handheld inhalers.
- AERO-111 Nebulized LABA/LAMA/ICS triple combination therapy for COPD currently in IND-enabling stage, designed for COPD patients who escalate beyond dual bronchodilators and require anti-inflammatory therapy in addition to bronchodilation.
Quantifiable outcome
- Placebo-adjusted FEV1 AUC0-24h of 251 mL (100/50 μg dose) and 262 mL (200/100 μg dose), both p<0.001
- +3 more outcomes
Companies that use AeroRx Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
AeroRx Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
AeroRx Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
AeroRx Therapeutics competitors and assessment
Company assessmentDirect peers
- Theravance Biopharma: Theravance developed YUPELRI (revefenacin), an FDA-approved nebulized LAMA for COPD, commercialized with Viatris. Most direct U.S. peer in nebulized COPD maintenance therapy, validating the commercial pathway AeroRx is pursuing.
- Sunovion Pharmaceuticals: Markets Lonhala Magnair, an FDA-approved nebulized glycopyrrolate (LAMA) for COPD, acquired from Elevation Pharma where AeroRx's CEO was co-founder/CMO. Closest direct competitor in the nebulized COPD maintenance segment.
Broad incumbents
- Viatris: Co-promotes YUPELRI with Theravance and has a broad respiratory and specialty portfolio. A likely strategic acquirer or commercial partner for an approved nebulized COPD asset like AERO-007.
- Respivant Sciences (Roivant): Acquired Patara Pharma (founded by AeroRx CEO) and develops inhaled therapies for respiratory diseases including COPD. Direct strategic linkage through the CEO and an indicator of the typical acquirer profile for a company at AeroRx's stage.
- GSK: Markets Trelegy Ellipta (LABA/LAMA/ICS) and Anoro Ellipta (LABA/LAMA) for COPD, the dominant dual/triple combination franchises. Most likely large-cap competitor that could develop a nebulized version of its combinations.
- AstraZeneca: Markets Breztri Aerosphere (LABA/LAMA/ICS) and Bevespi (LABA/LAMA) for COPD. Major respiratory incumbent with the resources and franchise to compete in or acquire nebulized COPD assets.
- Boehringer Ingelheim: Markets Spiriva (tiotropium) and Stiolto Respimat (LABA/LAMA) for COPD, the long-standing category leader in long-acting bronchodilators. Strategic competitor/partner for any nebulized COPD franchise.
- Teva Pharmaceutical: Markets ProAir RespiClick and has a significant respiratory generics and device portfolio, including nebulized products. Likely strategic competitor or commercial partner in the nebulized COPD space.
Emerging players
- Pulmatrix: Clinical-stage company developing inhaled therapies for respiratory diseases using proprietary iSPERSE dry powder technology. Comparable small-cap respiratory biotech peer in inhaled/nebulized drug delivery, though focused on different formulations.
- Inhalon Biopharma: Clinical-stage biopharma developing iSPERSE-based inhaled therapies for respiratory infections, with overlap in the inhaled respiratory therapy space. Emerging comparable in the small-cap nebulized/inhaled therapeutic category.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights7 records
Customer concentration
AeroRx Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
AeroRx Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
AeroRx Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AeroRx Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AeroRx Therapeutics
What does AeroRx Therapeutics do?
AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized fixed-dose combination therapies for moderate-to-severe COPD. Its lead candidate AERO-007 combines indacaterol (LABA) and glycopyrrolate (LAMA) in a proprietary solution formulation for delivery via a standard 510(k)-cleared jet nebulizer, while AERO-111 extends the approach to a nebulized LABA+LAMA+ICS triple combination.
Is AeroRx Therapeutics a public or private company?
AeroRx Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was AeroRx Therapeutics founded?
AeroRx Therapeutics was founded in 2022. It employs 1 to 10 people.
Where is AeroRx Therapeutics based?
AeroRx Therapeutics is headquartered in La Jolla, United States, in the North America region.
How does AeroRx Therapeutics make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are AeroRx Therapeutics's main competitors?
Direct peers on record are Theravance Biopharma and Sunovion Pharmaceuticals. Broad incumbents are Viatris, Respivant Sciences (Roivant), GSK, AstraZeneca, Boehringer Ingelheim and Teva Pharmaceutical. Emerging players are Pulmatrix and Inhalon Biopharma.
Does AeroRx Therapeutics have an API?
No public API is recorded for AeroRx Therapeutics.
What industry is AeroRx Therapeutics in?
AeroRx Therapeutics's product category is COPD Therapeutics. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals.